NZ708836A - Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides - Google Patents

Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides

Info

Publication number
NZ708836A
NZ708836A NZ708836A NZ70883613A NZ708836A NZ 708836 A NZ708836 A NZ 708836A NZ 708836 A NZ708836 A NZ 708836A NZ 70883613 A NZ70883613 A NZ 70883613A NZ 708836 A NZ708836 A NZ 708836A
Authority
NZ
New Zealand
Prior art keywords
inflammation
autoimmune
treatment
neurodegenerative disorders
derivative polypeptides
Prior art date
Application number
NZ708836A
Other languages
English (en)
Inventor
Joshua Goldberg
Colin Bier
Christoph Hotz-Behofsits
Sophie Hanscom
Original Assignee
Pin Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pin Pharma Inc filed Critical Pin Pharma Inc
Publication of NZ708836A publication Critical patent/NZ708836A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ708836A 2012-12-06 2013-12-06 Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides NZ708836A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734135P 2012-12-06 2012-12-06
US201361881266P 2013-09-23 2013-09-23
PCT/US2013/073658 WO2014089480A1 (en) 2012-12-06 2013-12-06 Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides

Publications (1)

Publication Number Publication Date
NZ708836A true NZ708836A (en) 2020-07-31

Family

ID=50884040

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ708836A NZ708836A (en) 2012-12-06 2013-12-06 Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides

Country Status (13)

Country Link
US (3) US9878001B2 (enExample)
EP (1) EP2928910B1 (enExample)
JP (2) JP6607784B2 (enExample)
CN (1) CN104981479B (enExample)
AU (1) AU2013355039B2 (enExample)
CA (1) CA2894166A1 (enExample)
DK (1) DK2928910T3 (enExample)
ES (1) ES2748423T3 (enExample)
IL (1) IL239271B (enExample)
NZ (1) NZ708836A (enExample)
RU (1) RU2653754C2 (enExample)
WO (1) WO2014089480A1 (enExample)
ZA (1) ZA201504100B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015051245A1 (en) * 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
EP3370738A2 (en) 2015-11-02 2018-09-12 Neuraltus Pharmaceuticals, Inc. Treatment of neurodegenerative disease with sodium chlorite
CN110290799A (zh) 2016-12-13 2019-09-27 防御素治疗学公司 用于治疗肺部炎性病症的方法
BR112023003865A2 (pt) * 2020-09-04 2024-03-12 Dompe Farm Spa Peptídeos dotados de atividade angiogênica
EP3964225A1 (en) * 2020-09-04 2022-03-09 Dompe' Farmaceutici S.P.A. Peptides endowed with angiogenic activity
US20230364112A1 (en) * 2020-09-29 2023-11-16 Alps Biotech Co., Ltd. Use of Antcin H and Its Derivatives for Treating Central Nervous System Diseases
JP2024533873A (ja) 2021-10-04 2024-09-12 ニューヴィヴォ， インコーポレイテッド Ａｌｓ患者の処置方法
WO2023062451A1 (en) * 2022-08-28 2023-04-20 Farhadi Andar Abi Ali Pegylated tat-efsevin-ta as an antiarrhythmic agent with favorable effect on heart failure caused by arrhythmia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
FR2792206B1 (fr) 1999-04-13 2006-08-04 Centre Nat Rech Scient Vaccin anti-vih-1 comprenant tout ou partie de la proteine tat de vih-1
US8323928B2 (en) 1999-08-12 2012-12-04 Pin Pharma, Inc. Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease
ATE465754T1 (de) 1999-08-12 2010-05-15 Inist Inc Nicht-immunsuppresives hiv tat-protein
US20050226890A1 (en) * 1999-08-12 2005-10-13 Cohen David I Tat-based vaccine compositions and methods of making and using same
US20080044435A1 (en) 2004-03-16 2008-02-21 Cohen David I Tat-Based Tolerogen Compositions and Methods of Making and Using Same
US20070248618A1 (en) 2004-03-16 2007-10-25 Cohen David I Tat-Based vaccine Compositions and Methods of Making and Using Same
NO314587B1 (no) * 2000-09-04 2003-04-14 Bionor Immuno As HIV regulatoriske- og hjelpepeptider, antigener, vaksinepreparater, immunoassay testsett og en metode for påvisning av antistoffer fremkaltav HIV
AP2368A (en) 2001-05-03 2012-02-27 Fit Biotech Oyj Plc Novel expression vectors and uses thereof.
US20050208482A1 (en) 2004-03-16 2005-09-22 Cohen David I Tat-based immunomodulatory compositions and methods for their discovery and use
US8530431B2 (en) * 2009-03-23 2013-09-10 Pin Pharma, Inc. Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides
WO2015051245A1 (en) * 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment

Also Published As

Publication number Publication date
EP2928910B1 (en) 2019-09-04
US20210069290A1 (en) 2021-03-11
CN104981479A (zh) 2015-10-14
US20140178420A1 (en) 2014-06-26
WO2014089480A1 (en) 2014-06-12
EP2928910A1 (en) 2015-10-14
CN104981479B (zh) 2021-06-01
ZA201504100B (en) 2016-05-25
CA2894166A1 (en) 2014-06-12
EP2928910A4 (en) 2016-06-29
JP2016508121A (ja) 2016-03-17
IL239271A0 (en) 2015-07-30
AU2013355039A1 (en) 2015-07-02
IL239271B (en) 2019-09-26
AU2013355039B2 (en) 2017-08-24
ES2748423T3 (es) 2020-03-16
HK1216318A1 (en) 2016-11-04
RU2015126776A (ru) 2017-01-13
JP6607784B2 (ja) 2019-11-20
US20180185441A1 (en) 2018-07-05
US9878001B2 (en) 2018-01-30
JP2019163259A (ja) 2019-09-26
RU2653754C2 (ru) 2018-05-14
DK2928910T3 (da) 2019-10-07

Similar Documents

Publication Publication Date Title
NZ708836A (en) Treatment of inflammation, autoimmune, and neurodegenerative disorders with immunosuppressive tat derivative polypeptides
WO2014145159A3 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
MX2016010953A (es) Proteinas de fc multimericas.
SA515360928B1 (ar) متقارنات جسم مضاد جديدة واستخداماتها
BR112016012997A2 (pt) Derivados de benzimidazóis tricíclicos fundidos como moduladores de atividade de tnf
JO3532B1 (ar) الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
HK1250238A1 (zh) 抗angptl8抗体及其用途
MX2011007647A (es) Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
NZ707086A (en) Anti-cd40 antibodies and methods of use
BR112016012990A2 (pt) Derivados de imidazol tricíclicos fundidos como moduladores de atividade de tnf
BR112017006669A2 (pt) derivados de imidazol pentacíclico fundido
EP2558124A4 (en) POLYSACCHARID COMPOSITIONS AND METHOD FOR USE THEREOF FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH PRECURSOR CELL MOBILIZATION
MX2015016741A (es) Inhibidores de pi3 cinasa delta y gama selectivos duales.
IN2014DN06792A (enExample)
HK1221424A1 (zh) 治疗癌症的药物组合
BR112016011789A2 (pt) Derivados de purina, composição farmacêutica compreendendo os mesmos e uso dos mesmos
BR112016012258A2 (pt) Derivados de tetra-hidrobenzimidazol como moduladores de atividade de tnf
BR112016012261A2 (pt) Derivados de tetra-hidroimidazopiridina como moduladores de atividade de tnf
MX2015003048A (es) Tratamiento del trastorno de estres post-traumatico con mycobacterium aislado.
WO2014184545A3 (en) Engineered fc variants
PH12013501671A1 (en) Methods for improving brain development and cognitive function using beta-hydroxy-beta-methylbutyrate
SI2968471T1 (sl) Peptidi za uporabo pri lokalnem zdravljenju nevrodegenerativnih bolezni mrežnice, zlasti v zgodnjih fazah diabetične retinopatije in drugih bolezni mrežnice, pri katerih igra nevrodegeneracija bistveno vlogo
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX2013011421A (es) Derivados de pirazolo-pirimidina.
MX2016006604A (es) Derivados de piperidina con actividad multimodal contra el dolor.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2021 BY DENNEMEYER + CO.

Effective date: 20201123

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2022 BY DENNEMEYER + CO.

Effective date: 20220228

ASS Change of ownership

Owner name: RESILION PHARMACEUTICALS, LLC, US

Effective date: 20220328

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2023 BY DENNEMEYER + CO.

Effective date: 20221129

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2024 BY DENNEMEYER + CO. S.A.R.L.

Effective date: 20231127

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2025 BY DENNEMEYER + CO. SARL

Effective date: 20241125

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 DEC 2026 BY DENNEMEYER ET CO

Effective date: 20251125